Cyclerion appoints Regina Graul as President; CEO Peter Hecht transitions to strategic consultant

Cyclerion Therapeutics, Inc.

Regina Graul, Ph.D., appointed President effective Dec 1, 2023; CEO Peter Hecht steps down but remains strategic consultant and board member.
Graul earns $372K base salary, bonuses up to $125K, and up to 100K restricted shares vesting over time.
Graul previously VP at EQRx and olinciguat program lead at Cyclerion; 15+ years at Ironwood Pharmaceuticals.
Hecht completed transitional assignment; Cyclerion to rebuild with board additions Dina Katabi and Michael Higgins.
Company to evaluate existing assets and pursue external innovation for next phase.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Regina Graul

President

CYCN · Cyclerion Therapeutics, Inc.

Effective: 2023-12-01
Filed: December 4, 2023, 6:59 PM ET

On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) unanimously elected Regina Graul Ph.D., as President of the Company, effective December 1, 2023.

Departed

Peter Hecht

President and Chief Executive Officer

CYCN · Cyclerion Therapeutics, Inc.

Effective: 2023-11-30
Successor: Regina Graul
Filed: December 4, 2023, 6:59 PM ET

She replaces Peter Hecht, Ph.D., who resigned on November 30, 2023 as President and Chief Executive Officer to pursue his responsibilities as President of Tisento.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Regina Graul was elected as President at Cyclerion Therapeutics, Inc..

Action: elected
Role: President

Exact text from the filing

On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) unanimously elected Regina Graul Ph.D., as President of the Company, effective December 1, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Hecht resigned as President and Chief Executive Officer at Cyclerion Therapeutics, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

She replaces Peter Hecht, Ph.D., who resigned on November 30, 2023 as President and Chief Executive Officer to pursue his responsibilities as President of Tisento.

View on SEC.gov

Cyclerion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-288498

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.